menu
    • menu
    [{"orgOrder":0,"company":"Sensorium Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"SENS-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sensorium Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Sensorium Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sensorium Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensorium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SNTX-2643","moa":"5-HT","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sensorium Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorium Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Sensorium Therapeutics

    Menu

    Sensorium Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sensorium Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Sensorium Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNTX-2643

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sensorium Gets FDA IND Clearance for Rapid-Acting Anxiety Drug SNTX-2643

                            Details : SNTX-2643 is a first-in-class precision serotonin modulator designed to treat neuropsychiatric conditions including social anxiety disorder.

                            Product Name : SNTX-2643

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 08, 2025

                            Lead Product(s) : SNTX-2643

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sensorium Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Sensorium Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENS-01

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Sensorium Raises $30M in Series A Round To Probe Plants, Fungi For Psychoactive Natural Products

                            Details : SENS-01 shows promise to deliver rapid therapeutic effect for treating anxiety. Sensorium is developing SENS-01 as a rapid-acting and well-tolerated therapeutic for patients with anxiety and depression.

                            Product Name : SENS-01

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 11, 2022

                            Lead Product(s) : SENS-01

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth